1. Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
- Author
-
Wang, Yang, Zhou, Xiaobing, Wu, Zhen, Hu, Han, Jin, Jing, Hu, Yanping, Dong, Yuting, Zou, Jianwen, Mao, Zeyong, Shi, Xiaotai, Huo, Yan, Lyu, Jianjun, Fang, Zhizheng, Zhang, Wen, Zhu, Yujie, Li, Bo, and Liu, Binlei
- Subjects
- *
HERPES simplex virus , *ACUTE toxicity testing , *KRA , *TOXICITY testing - Abstract
Oncolytic virotherapy is a new and safe therapeutic strategy based on the inherent cytotoxicity of oncolytic viruses and their ability to replicate and spread within tumors in a selective manner. In a previous study, a new type of oncolytic herpes simplex virus type 2 (oHSV-2, named OH2) was constructed to treat human cancers. That study demonstrated that OH2 is genetically and biologically stable. Its antitumor activity was maintained, even after passaging the virus for >20 generations. To advance OH2 into a clinical trial, a systematic preclinical safety evaluation was performed, which included: an acute toxicity test of OH2 in BALB/c mice; repeated dose toxicity tests of OH2 in BALB/c mice and cynomolgus monkeys; and biodistribution assays of OH2 in BALB/c mice, tumor-bearing mice, tumor-bearing nude mice, and cynomolgus monkeys. The results of this preclinical safety evaluation of OH2 indicate that OH2 is safe and suitable for clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF